ArQule reported a loss of 10 cents per share in the third quarter of 2013, narrower than the Zacks Consensus Estimate of a loss of 13 cents per share.
The following U.S.- and Canada-listed companies reported earnings on Thursday. This list shows whether they beat, met or missed Wall Street analysts' forecasts. It also shows the difference between analysts' ...
Paolo Pucci Thank you, Bill. Good morning, everybody, and thank you for joining us today on this call.
The following audio is from a conference call that will begin on November 07, 2013 at 09:00 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion.
Conference call scheduled today at 9:00 a.m. eastern time WOBURN, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (NASDAQ: ARQL) today reported its results of operations for the fiscal quarter and nine months ended ...
ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsNov 7
WOBURN, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the third quarter of 2013 on Thursday, November 7, 2013 at 7:00 a.m. Eastern Time. ...
ArQule continues to focus its efforts on developing lead candidate tivantinib (ARQ 197) after having suffered a few setbacks earlier in the year.
Data Presented at European Cancer Congress Suggest Clinical Benefit of Tivantinib in Patients with MET High Non-Squamous Non-Small Cell Lung CancerBusiness Wire Sep 30
Data presented at the European Cancer Congress demonstrated clinical benefits of treatment with the combination of tivantinib and erlotinib in patients with non-squamous, non-small